

# Ceporex Vet 250

## Introduction



Company name: [Intervet / Schering-Plough Animal Health](#)  
Address: **Walton Manor**  
**Walton**  
**Milton Keynes**  
**MK7 7AJ**  
Telephone: **01908 685685**  
Fax: **01908 685555**  
Email: [support.uk@intervet.com](mailto:support.uk@intervet.com)  
Website: [www.intervet.co.uk](http://www.intervet.co.uk)

## Presentation

Ceporex Vet 250 Tablets are pink, convex, film-coated tablets, each containing 250 mg cefalexin Ph Eur.

## Uses

The Tablets are indicated for oral antibiotic therapy in dogs. Cefalexin is a broad spectrum cephalosporin antibiotic with bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria.

The following micro-organisms have been shown to be sensitive to cefalexin *in vitro*: *Staphylococcus* spp (including penicillin-resistant strains), *Streptococcus* spp, *Corynebacterium* spp, *Pasteurella multocida*, *Escherichia coli*, *Micrococcus* spp, *Moraxella* spp.

When susceptible organisms are present, the tablets may be effective in the treatment of infections of the respiratory tract, urogenital tract, the skin and localised infections in soft tissue.

In dogs it may also be effective in the treatment of infections of the gastrointestinal tract.

## Dosage and administration

The recommended dose rate is 10 to 15 mg/kg bodyweight twice daily.

The following is intended as a guide.

### Dogs

51 kg and over bodyweight: 3×250 mg tablets twice daily.

26 to 50 kg bodyweight: 2×250 mg tablets twice daily.

10 to 25 kg bodyweight: 1×250 mg tablets twice daily.

Treatment for five days is recommended.

Any variation should be at the discretion of the prescribing veterinary surgeon, e.g. in cases where the condition requires an extended course of treatment (such as chronic pyoderma).

The Tablets are well accepted by dogs but may be crushed or added to food if necessary.

## Contra-indications, warnings, etc

There are no contra-indications.

Hypersensitivity to cefalexin is rare, however the tablets should not be administered to animals which are known to be hypersensitive to cefalexin.

As with other antibiotics which are excreted mainly by the kidneys, unnecessary accumulation may occur in the body when renal function is impaired. In cases of known renal insufficiency the dose should be reduced.

Keep out of reach of children.

For animal treatment only.

### Operator warnings

Cephalosporins may cause sensitisation (allergy) following injection, inhalation, ingestion or skin contact. Sensitivity to penicillin may lead to cross sensitivity to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious.

1. Do not handle this product (or these products) if you know you are sensitised, or if you have been advised not to work with such preparations.
2. Handle this product with great care to avoid exposure, taking all recommended precautions.
3. If you develop symptoms following exposure such as a skin rash you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.

Wash hands after use.

## Pharmaceutical precautions

Do not store above 25°C. Protect from light.

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

## Legal category

POM-V (previously POM)

## Packaging Quantities

The Tablets are supplied in packs of 100 and 250 tablets.

**Further information**

Cefalexin is rapidly, and almost completely, absorbed after oral administration. Effective blood levels are generally achieved within two hours of dosing. Cefalexin is excreted in the urine in high concentration.

Cefalexin is resistant to the action of staphylococcal penicillinase and is therefore active against the strains of *Staphylococcus aureus* that are insensitive to penicillin (or related antibiotics such as ampicillin or amoxycillin) because of production of penicillinase. Cefalexin is also active against the majority of ampicillin-resistant *E. coli*.

The administration of cefalexin has been shown to produce no serious side-effects at many times the recommended dose rate.

**Marketing authorisation number**

Vm 0201/4075.